tetano
Editor, Senior Moderator
J Clin Med
. 2023 Oct 9;12(19):6415.
doi: 10.3390/jcm12196415. Bleeding Complications in COVID-19 Critically Ill ARDS Patients Receiving VV-ECMO Therapy
Armin Niklas Flinspach[SUP] 1 [/SUP], Dorothée Bobyk[SUP] 1 [/SUP], Kai Zacharowski[SUP] 1 [/SUP], Vanessa Neef[SUP] 1 [/SUP], Florian Jürgen Raimann[SUP] 1 [/SUP]
Affiliations
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) therapy is rapidly expanding worldwide, yet this therapy has a serious risk of bleeding. Whether coagulation-activating viral infections such as COVID-19 may have an impact on the risk of bleeding is largely unknown. This study conducted a monocentric investigation of severely affected COVID-19 patients receiving VV-ECMO therapy with regard to the occurrence and possible influences of minor and major bleeding and transfusion requirements. Among the 114 included study patients, we were able to assess more than 74,000 h of VV-ECMO therapy. In these, 103 major bleeding events and 2283 minor bleeding events were detected. In total, 1396 red blood concentrates (RBCs) were administered. A statistically significant correlation with the applied anticoagulation or demographic data of the patients was not observed. Contrary to the frequently observed thromboembolic complications among COVID-19 patients, patients with VV-ECMO therapy, even under low-dose anticoagulation, show a distinct bleeding profile, especially of minor bleeding, with a substantial need for blood transfusions. COVID-19 patients show a tendency to have frequent bleeding and require repeated RBC transfusions during VV-ECMO. This fact might not be solely explained by the mechanical alteration of ECMO or anticoagulation.
Keywords: acute respiratory distress syndrome; anticoagulation; bleeding; critical care; extracorporeal membrane oxygenation; severe acute respiratory syndrome coronavirus 2; transfusion.
. 2023 Oct 9;12(19):6415.
doi: 10.3390/jcm12196415. Bleeding Complications in COVID-19 Critically Ill ARDS Patients Receiving VV-ECMO Therapy
Armin Niklas Flinspach[SUP] 1 [/SUP], Dorothée Bobyk[SUP] 1 [/SUP], Kai Zacharowski[SUP] 1 [/SUP], Vanessa Neef[SUP] 1 [/SUP], Florian Jürgen Raimann[SUP] 1 [/SUP]
Affiliations
- PMID: 37835059
- PMCID: PMC10573698
- DOI: 10.3390/jcm12196415
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) therapy is rapidly expanding worldwide, yet this therapy has a serious risk of bleeding. Whether coagulation-activating viral infections such as COVID-19 may have an impact on the risk of bleeding is largely unknown. This study conducted a monocentric investigation of severely affected COVID-19 patients receiving VV-ECMO therapy with regard to the occurrence and possible influences of minor and major bleeding and transfusion requirements. Among the 114 included study patients, we were able to assess more than 74,000 h of VV-ECMO therapy. In these, 103 major bleeding events and 2283 minor bleeding events were detected. In total, 1396 red blood concentrates (RBCs) were administered. A statistically significant correlation with the applied anticoagulation or demographic data of the patients was not observed. Contrary to the frequently observed thromboembolic complications among COVID-19 patients, patients with VV-ECMO therapy, even under low-dose anticoagulation, show a distinct bleeding profile, especially of minor bleeding, with a substantial need for blood transfusions. COVID-19 patients show a tendency to have frequent bleeding and require repeated RBC transfusions during VV-ECMO. This fact might not be solely explained by the mechanical alteration of ECMO or anticoagulation.
Keywords: acute respiratory distress syndrome; anticoagulation; bleeding; critical care; extracorporeal membrane oxygenation; severe acute respiratory syndrome coronavirus 2; transfusion.